Cost-effectiveness of expanding national health insurance coverage for composite resin restorations in cancer patients in South Korea

被引:0
作者
Han, Areum [1 ,2 ]
Park, Eun-Gee [1 ]
Yoon, Jeong-Hwa [3 ]
Choi, Ji-Yeob [4 ,5 ]
Park, Hee-Kyung [6 ,7 ]
Hahn, Seokyung [3 ,5 ,8 ]
机构
[1] Seoul Natl Univ, Coll Med, Interdisciplinary Program Med Informat, Seoul, South Korea
[2] Seoul Natl Univ, Coll Med, Integrated Major Innovat Med Sci, Seoul, South Korea
[3] Seoul Natl Univ, Med Bigdata Res Ctr, Med Res Ctr, Seoul, South Korea
[4] Seoul Natl Univ, Grad Sch, Dept Biomed Sci, Seoul, South Korea
[5] Seoul Natl Univ, Inst Hlth Policy & Management, Med Res Ctr, Seoul, South Korea
[6] Seoul Natl Univ, Sch Dent, Dept Oral Med & Oral Diag, Seoul, South Korea
[7] Seoul Natl Univ, Dent Res Inst, Seoul, South Korea
[8] Seoul Natl Univ, Coll Med, Dept Human Syst Med, 103 Daehak Ro, Seoul 03080, South Korea
基金
新加坡国家研究基金会;
关键词
Cancer patients; Dental insurance; National health insurance; Markov model; Cost-effectiveness analysis; Resin composite; Insurance coverage; XEROSTOMIC HEAD; DENTAL DISEASE; GLASS-IONOMER; ORAL-CANCER; NECK; THERAPY; MANAGEMENT; CARCINOMA; MUCOSITIS; CARIES;
D O I
10.1016/j.jdent.2024.105357
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objectives: Cancer patients often have compromised oral health, making them vulnerable to severe dental caries and restoration failures. Due to the nature of cervical or anterior caries in cancer patients, the use of adequate restorative materials is important. However, public dental insurance coverage for composite treatments varies among countries and only glass ionomer cements (GICs) are covered in all age groups in South Korea. This study examined the cost-effectiveness of expanding national health insurance coverage to include resin composite (RC) restorations as compared with GIC in cancer patients. Methods: Data from cancer patients who received direct restoration using GIC were identified from the National Health Screening Cohort. The relative effect of RC compared to GIC was determined through a meta-analysis, which was then utilized in calculating corresponding transition probabilities within a multi-state model. A Markov-chain Monte Carlo microsimulation was performed to estimate useful life-years and total treatment costs at the tooth level. The incremental cost-effectiveness ratio (ICER) of RC versus GIC was calculated, considering scenarios with and without expanded national health insurance coverage. The robustness of the results was confirmed through various sensitivity analyses. Results: Between the two materials, RC resulted in a 0.4-year longer useful life. From a limited societal perspective, it cost $9.6 less with expanded coverage but $24.3 more without expansion, resulting in an ICER of -$25.2 and $63.9 per tooth-year, respectively. From a patient's perspective, the ICER values were -$72.7 versus $138.8 per tooth-year, respectively, translating into $200 more in savings with the expansion. Various sensitivity analyses consistently demonstrated a smaller ICER when insurance coverage was expanded. Conclusions: The expansion of national health insurance coverage to include RC restorations for cancer patients appears to be clearly cost-effective. This emphasizes the need for further policy considerations to ensure access to dental care for cancer patients. Clinical Significance: Timely management of dental caries is crucial for cancer patients, as untreated caries can escalate into severe oral conditions, negatively impacting treatment outcomes and increasing care costs. Expanding a national health insurance coverage for cancer patients in the treatment of early dental lesions is necessary to prevent advanced dental diseases.
引用
收藏
页数:8
相关论文
共 36 条
  • [31] Comparative Cost-effectiveness of Robot-assisted and Standard Laparoscopic Prostatectomy as Alternatives to Open Radical Prostatectomy for Treatment of Men with Localised Prostate Cancer: A Health Technology Assessment from the Perspective of the UK National Health Service
    Close, Andrew
    Robertson, Clare
    Rushton, Stephen
    Shirley, Mark
    Vale, Luke
    Ramsay, Craig
    Pickard, Robert
    EUROPEAN UROLOGY, 2013, 64 (03) : 361 - 369
  • [32] Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
    Zi-Rong Chen
    Chen-Han Chueh
    Nai-Jung Chiang
    Yi-Wen Tsai
    Cost Effectiveness and Resource Allocation, 21
  • [33] Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service
    Armeni, Patrizio
    Borsoi, Ludovica
    Fornaro, Giulia
    Jommi, Claudio
    Grossi, Francesco
    Costa, Francesco
    CLINICAL THERAPEUTICS, 2020, 42 (05) : 830 - 847
  • [34] Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
    Chen, Zi-Rong
    Chueh, Chen-Han
    Chiang, Nai-Jung
    Tsai, Yi-Wen
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [35] Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service
    Armeni, Patrizio
    Borsoi, Ludovica
    Fornaro, Giulia
    Jommi, Claudio
    Colombo, Nicoletta
    Costa, Francesco
    CLINICAL THERAPEUTICS, 2020, 42 (07) : 1192 - +
  • [36] Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health-Care System in China
    Zhu, Chen
    Xing, Xiao-xuan
    Wu, Bin
    Liang, Gang
    Han, Gang
    Lin, Cai-xia
    Fang, Hong-mei
    FRONTIERS IN PHARMACOLOGY, 2021, 12